| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
449,967 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$81,866,696 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
69 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Akkaraju Srinivas |
Director |
– • – |
2007-02-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,015,139 |
94,520 |
|
- |
|
| Dobmeier Eric |
Sr. VP, Corporate Development |
• – – |
2007-02-09 |
4 |
S |
$8.90 |
$446,955 |
D/D |
(50,000) |
1,798 |
|
- |
|
| Dobmeier Eric |
Sr. VP, Corporate Development |
• – – |
2007-02-09 |
4 |
OE |
$2.70 |
$184,395 |
D/D |
43,472 |
5,198 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2007-02-06 |
4 |
S |
$9.23 |
$1,615,320 |
I/I |
(175,000) |
5,132,750 |
|
- |
|
| Delphi Bioinvestments Vi Lp |
10% Owner |
– – • |
2007-01-17 |
4 |
A |
$0.00 |
$0 |
I/I |
19,800 |
2,000,000 |
|
- |
|
| Delphi Bioinvestments Vi Lp |
10% Owner |
– – • |
2007-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,980,200 |
1,980,200 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2007-01-03 |
4 |
S |
$5.22 |
$130,488 |
I/I |
(25,000) |
5,308,300 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-12-15 |
4 |
S |
$5.70 |
$1,425,000 |
I/I |
(250,000) |
5,333,300 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-12-14 |
4 |
S |
$5.72 |
$286,185 |
I/I |
(50,000) |
5,583,300 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-11-10 |
4 |
S |
$5.45 |
$272,615 |
I/I |
(50,000) |
5,633,300 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-11-09 |
4 |
S |
$5.56 |
$556,080 |
I/I |
(100,000) |
5,683,300 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-10-12 |
4 |
S |
$4.95 |
$352,414 |
I/I |
(71,156) |
5,783,300 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-10-11 |
4 |
S |
$4.95 |
$87,264 |
I/I |
(17,644) |
5,854,456 |
|
- |
|
| Gallen Jonathan |
10% Owner |
– – • |
2006-10-10 |
4 |
S |
$4.98 |
$55,780 |
I/I |
(11,200) |
5,872,100 |
|
- |
|
| Berger Franklin M |
Director |
– • – |
2006-08-15 |
4 |
A |
$4.18 |
$41,977 |
D/D |
10,000 |
71,692 |
|
- |
|
| Baker Felix |
Director |
– • • |
2006-08-14 |
4 |
B |
$4.05 |
$3,443 |
I/I |
850 |
95,159 |
2.17 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-14 |
4 |
B |
$4.05 |
$150,134 |
I/I |
37,070 |
4,149,611 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-14 |
4 |
B |
$4.05 |
$48,924 |
I/I |
12,080 |
1,535,999 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-11 |
4 |
B |
$4.03 |
$429,591 |
I/I |
106,622 |
4,112,541 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-11 |
4 |
B |
$4.03 |
$139,991 |
I/I |
34,745 |
1,523,919 |
2.25 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-11 |
4 |
B |
$4.03 |
$9,855 |
I/I |
2,446 |
94,309 |
2.17 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-10 |
4 |
B |
$4.03 |
$14,503 |
I/I |
3,597 |
4,005,919 |
2.17 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-10 |
4 |
B |
$4.03 |
$4,725 |
I/I |
1,172 |
1,489,174 |
2.17 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-10 |
4 |
B |
$4.03 |
$335 |
I/I |
83 |
91,863 |
2.17 |
- |
|
| Baker Felix |
Director |
– • • |
2006-08-09 |
4 |
B |
$4.05 |
$791,152 |
I/I |
195,347 |
3,978,746 |
2.25 |
- |
|
1805 Records found
|
|
Page 61 of 73 |
|
|
